PT3060908T - Diagnóstico e tratamento de doenças autoimunes - Google Patents

Diagnóstico e tratamento de doenças autoimunes

Info

Publication number
PT3060908T
PT3060908T PT148550023T PT14855002T PT3060908T PT 3060908 T PT3060908 T PT 3060908T PT 148550023 T PT148550023 T PT 148550023T PT 14855002 T PT14855002 T PT 14855002T PT 3060908 T PT3060908 T PT 3060908T
Authority
PT
Portugal
Prior art keywords
diagnosis
treatment
autoimmune diseases
autoimmune
diseases
Prior art date
Application number
PT148550023T
Other languages
English (en)
Portuguese (pt)
Original Assignee
Dyax Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dyax Corp filed Critical Dyax Corp
Publication of PT3060908T publication Critical patent/PT3060908T/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PT148550023T 2013-10-21 2014-10-17 Diagnóstico e tratamento de doenças autoimunes PT3060908T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361893542P 2013-10-21 2013-10-21

Publications (1)

Publication Number Publication Date
PT3060908T true PT3060908T (pt) 2021-05-27

Family

ID=52993412

Family Applications (1)

Application Number Title Priority Date Filing Date
PT148550023T PT3060908T (pt) 2013-10-21 2014-10-17 Diagnóstico e tratamento de doenças autoimunes

Country Status (14)

Country Link
US (3) US10101344B2 (enExample)
EP (2) EP3060908B1 (enExample)
JP (3) JP6657098B2 (enExample)
KR (3) KR102485948B1 (enExample)
CN (2) CN110658337B (enExample)
AU (4) AU2014340449B2 (enExample)
BR (1) BR112016008975B1 (enExample)
CA (1) CA2927695C (enExample)
DK (1) DK3060908T3 (enExample)
ES (1) ES2873204T3 (enExample)
IL (4) IL284969B (enExample)
PL (1) PL3060908T3 (enExample)
PT (1) PT3060908T (enExample)
WO (1) WO2015061182A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL273688B2 (en) * 2013-01-20 2024-12-01 Dyax Corp Evaluation and treatment of bradykinin-mediated disorders
KR20250066486A (ko) 2013-10-21 2025-05-13 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
WO2015061182A1 (en) * 2013-10-21 2015-04-30 Dyax Corp. Diagnosis and treatment of autoimmune diseases
WO2017070170A1 (en) * 2015-10-19 2017-04-27 Dyax Corp. Immunoassay to detect cleaved high molecular weight kininogen
MX2019002932A (es) * 2016-09-16 2019-07-15 Dyax Corp Biomarcadores proteicos para enfermedades asociadas con el sistema de activacion por contacto.
KR200490846Y1 (ko) 2019-04-09 2020-01-13 이대호 각도조절 브라켓
EP4126219A2 (en) * 2020-04-04 2023-02-08 Takeda Pharmaceutical Company Limited Plasma kallikrein inhibitors and uses thereof for treating acute respiratory distress syndrome
KR20230050770A (ko) 2021-10-08 2023-04-17 김경민 발로 열 수 있는 반려동물 울타리
EP4548103A2 (en) * 2022-06-30 2025-05-07 Takeda Pharmaceutical Company Limited Protein biomarkers for lanadelumab treatment

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
CA1312564C (en) 1985-07-12 1993-01-12 Robert W. Colman Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US5047323A (en) 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
JPS63185398A (ja) 1986-09-10 1988-07-30 Nippon Zoki Pharmaceut Co Ltd 生理活性物質測定法
US4882272A (en) 1986-10-01 1989-11-21 Temple University - Of The Commonwealth System Of Higher Education High molecular weight kininogen assay
US5025796A (en) * 1988-12-01 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU675916B2 (en) 1991-06-14 1997-02-27 Genentech Inc. Method for making humanized antibodies
US5472945A (en) 1991-08-13 1995-12-05 Temple University- Of The Commonwealth System Of Higher Education Modulation of blood pressure and inhibition of platelet activation with kininogen fragment
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
EP0739355B1 (en) 1994-01-11 2004-09-08 Dyax Corporation Kallikrein-inhibiting "kunitz domain" proteins and analogues thereof
EP0852004B1 (en) 1995-10-11 2011-01-19 Luminex Corporation Multiplexed analysis of clinical specimens
JPH1084995A (ja) 1996-09-12 1998-04-07 Nippon Zoki Pharmaceut Co Ltd 血液凝固第ｘｉｉ因子活性化法
US5789261A (en) 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
US6242210B1 (en) 1997-05-20 2001-06-05 Actinova Limited Treatment of bacterial infections
DE69833755T2 (de) 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
EP1051432B1 (en) 1998-12-08 2007-01-24 Biovation Limited Method for reducing immunogenicity of proteins
JP4346798B2 (ja) 1999-08-19 2009-10-21 協和メデックス株式会社 Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。
US6994852B1 (en) 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US7678541B2 (en) 2000-11-21 2010-03-16 Hologic, Inc. Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction
JP2002221519A (ja) 2001-01-29 2002-08-09 Sysmex Corp 抗凝固剤およびそれを用いた抗凝固剤処理方法
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
JP4303105B2 (ja) 2001-06-28 2009-07-29 ドマンティス リミテッド 二重特異性リガンドとその利用
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
JP4106888B2 (ja) 2001-09-19 2008-06-25 カシオ計算機株式会社 液晶表示装置および携帯端末装置
US8148171B2 (en) 2001-10-09 2012-04-03 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
US7064107B2 (en) 2002-06-07 2006-06-20 Dyax Corp. Prevention and reduction of blood loss
WO2004001065A2 (en) 2002-06-24 2003-12-31 Cornell Research Foundation, Inc. Exhaustive selection or rna aptamers against complex targets
US20070003552A1 (en) 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
AU2003280241A1 (en) 2002-11-01 2004-05-25 Mcmaster University Multicomponent protein microarrays
US7329742B2 (en) 2003-09-04 2008-02-12 The Regents Of The University Of California Aptamers and methods for their in vitro selection and uses thereof
US7807351B2 (en) 2003-11-22 2010-10-05 Techno Medica Co., Ltd. Method of detecting target molecule by using aptamer
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
EP3613767A1 (en) 2005-05-18 2020-02-26 Ablynx N.V. Improved nanobodiestm against tumor cecrosis factor-alpha
AU2006332774A1 (en) 2005-12-29 2007-07-12 Dyax Corp. Protease inhibition
US7625944B2 (en) 2006-07-31 2009-12-01 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
EP2089712A4 (en) * 2006-11-22 2010-09-22 Life Technologies Corp BIOMARKERS OF AUTOIMMUNE DISEASES
WO2008100791A1 (en) 2007-02-16 2008-08-21 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of sickle cell
US20090075887A1 (en) * 2007-08-21 2009-03-19 Genzyme Corporation Treatment with Kallikrein Inhibitors
CA2703264A1 (en) 2007-10-22 2009-04-30 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
WO2010004962A1 (ja) * 2008-07-07 2010-01-14 日本臓器製薬株式会社 線維筋痛症の検査法
US20110212104A1 (en) 2008-11-03 2011-09-01 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
WO2010065656A1 (en) 2008-12-02 2010-06-10 Joslin Diabetes Center Method for reducing blood pressure using inhibitors of plasma kallikrein
US8637454B2 (en) 2009-01-06 2014-01-28 Dyax Corp. Treatment of mucositis with kallikrein inhibitors
FR2942233B1 (fr) 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
KR101077275B1 (ko) * 2009-05-07 2011-10-27 한국기초과학지원연구원 당단백질의 당쇄화를 이용한 암 진단 방법
JP5299179B2 (ja) * 2009-09-02 2013-09-25 株式会社リコー 画像形成装置
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US9206123B2 (en) * 2009-12-18 2015-12-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
KR20120120237A (ko) 2009-12-18 2012-11-01 액티브사이트 파마슈티칼즈, 인크. 혈장 칼리크레인 억제제의 전구약물
AU2011204349C1 (en) 2010-01-06 2017-02-16 Takeda Pharmaceutical Company Limited Plasma kallikrein binding proteins
EP2593121A2 (en) * 2010-07-13 2013-05-22 University Of Rochester THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
CN103384496B (zh) 2010-12-02 2016-10-12 贝克顿·迪金森公司 含有血液稳定剂的血液收集装置
WO2012094587A1 (en) * 2011-01-06 2012-07-12 Dyax Corp. Plasma kallikrein binding proteins
WO2012170945A2 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
US9187749B2 (en) * 2011-06-10 2015-11-17 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
IL273688B2 (en) 2013-01-20 2024-12-01 Dyax Corp Evaluation and treatment of bradykinin-mediated disorders
AU2014212194A1 (en) 2013-02-01 2015-09-17 Becton, Dickinson And Company Blood collection devices containing contact pathway inhibition additives
WO2015061182A1 (en) 2013-10-21 2015-04-30 Dyax Corp. Diagnosis and treatment of autoimmune diseases
KR20250066486A (ko) 2013-10-21 2025-05-13 다케다 파머수티컬 컴패니 리미티드 혈장 칼리크레인 시스템 바이오마커를 결정하기 위한 검정법
ES2856076T3 (es) 2014-01-21 2021-09-27 Takeda Pharmaceuticals Co Proteínas de unión a calicreína plasmática y usos de las mismas en el tratamiento de angioedema hereditario
WO2017070170A1 (en) 2015-10-19 2017-04-27 Dyax Corp. Immunoassay to detect cleaved high molecular weight kininogen
IL312919B1 (en) 2015-12-15 2025-10-01 Takeda Pharmaceuticals Co Peptide assay to distinguish between full-length high molecular weight kinogen (HMWK) and cleaved HMWK
EP4096687A4 (en) * 2020-01-28 2024-02-28 Orgenesis Inc. Process and system for acellular therapy

Also Published As

Publication number Publication date
AU2014340449A1 (en) 2016-06-02
JP7541560B2 (ja) 2024-08-28
EP3060908A4 (en) 2017-03-22
KR102665705B1 (ko) 2024-05-14
KR102485948B1 (ko) 2023-01-06
US12061206B2 (en) 2024-08-13
US20200371120A1 (en) 2020-11-26
CA2927695A1 (en) 2015-04-30
BR112016008975B1 (pt) 2023-02-28
CN105874332B (zh) 2019-11-12
AU2024266697A1 (en) 2024-12-12
PL3060908T3 (pl) 2021-10-25
KR20230010003A (ko) 2023-01-17
JP2017500584A (ja) 2017-01-05
ES2873204T3 (es) 2021-11-03
WO2015061182A1 (en) 2015-04-30
AU2022204649B2 (en) 2024-08-22
US10648990B2 (en) 2020-05-12
IL275368A (en) 2020-07-30
JP2020091296A (ja) 2020-06-11
US10101344B2 (en) 2018-10-16
AU2020200423B2 (en) 2022-03-31
BR112016008975A2 (pt) 2017-09-19
IL284969B (en) 2022-07-01
JP2022191343A (ja) 2022-12-27
KR102295623B1 (ko) 2021-08-31
AU2022204649A1 (en) 2022-07-21
CN110658337B (zh) 2023-06-16
AU2020200423A1 (en) 2020-02-13
IL293948A (en) 2022-08-01
KR20160089368A (ko) 2016-07-27
EP3060908B1 (en) 2021-02-24
IL245206A0 (en) 2016-06-30
EP3060908A1 (en) 2016-08-31
IL284969A (en) 2021-08-31
DK3060908T3 (da) 2021-05-25
JP7157089B2 (ja) 2022-10-19
EP3913364A1 (en) 2021-11-24
CN105874332A (zh) 2016-08-17
KR20210107182A (ko) 2021-08-31
IL275368B (en) 2021-08-31
CA2927695C (en) 2022-03-01
US20160252533A1 (en) 2016-09-01
CN110658337A (zh) 2020-01-07
JP6657098B2 (ja) 2020-03-04
AU2014340449B2 (en) 2019-10-31
IL245206B (en) 2020-06-30
US20190120862A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
IL273688A (en) Evaluation and treatment of bradykinin-mediated disorders
IL284969A (en) Diagnosis and treatment of autoimmune diseases
GB201302447D0 (en) Therapeutic and diagnostic target
EP2958936A4 (en) METHOD AND COMPOSITIONS FOR TREATING CORI DISEASE
HUE064634T2 (hu) Kardiovaszkuláris betegségek kezelése
EP3084000A4 (en) Method of diagnosis and treatment
EP3013425A4 (en) Treatment and diagnosis of ocular disease
EP3046629A4 (en) Treatment of inflammatory skin disease
EP2964227A4 (en) TREATMENT AND PROPHYLAXIS OF RENAL DISEASES
GB201303308D0 (en) Therapeutic and diagnostic target
EP3016968A4 (en) Diagnosis and treatment of autoimmune diseases
GB201309498D0 (en) Novel diagnosis and therapy
AU2013902435A0 (en) Diagnosis and treatment of autoimmune diseases
GB201301685D0 (en) Diagnosis and treatment of cancer
GB201321628D0 (en) Treatment of disease
GB201306413D0 (en) The local treatment of ophthalmic diseases
AU2013904912A0 (en) Method of Diagnosis and Treatment
GB201319053D0 (en) Therapeutic and diagnostic target
GB201303298D0 (en) Therapeutic and diagnostic target
GB201303292D0 (en) Therapeutic and diagnostic target
GB201303311D0 (en) Therapeutic and diagnostic target
GB201303317D0 (en) Therapeutic and diagnostic target
GB201302817D0 (en) Therapeutic and diagnostic target
GB201302384D0 (en) Therapeutic and diagnostic target
GB201302329D0 (en) Therapeutic and diagnostic target